Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial
Keywords:
Heart failure
Spironolactone
Atrial remodelling
Collagen cross-linking
Note:
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License
Citation:
Ravassa, S. (Susana); López, B. (Begoña); Ferreira, J.P. (João Pedro); et al. "Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial". European Journal of Heart Failure. (24), 2022, 321 - 331
Statistics and impact
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.